The British reimbursement agency, the National Institute for Health and Care Excellence (NICE), has provided a positive recommendation for an Opdivo (nivolumab) combination therapy.
Developed by US firm Bristol Myers Squibb (NYSE: BMY), the checkpoint blocker has been developed for use, in combination with chemotherapy, for certain adults with gastric and gastro-oesophageal junction (GOJ) cancers.
Recognizing that there is an unmet need for alternative treatments for this patient population, scientists at the NICE said the combo met its end-of-life criteria.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze